Secret leprosy infected the Americas before European arrival – DW – 06/04/2025
European colonizers were thought to have brought leprosy to the Americas, but a new study reveals it existed there for thousands of years and spread by a recently discovered bacteria species.
What to know:
Leprosy is one of the oldest human diseases and originated in Eurasia or Africa.
A new study has found a different species of leprosy-causing bacteria existed in the Americas before European settlement.
Scientists once believed Europeans brought leprosy to the American continents via infection from the bacterial species Mycobacterium leprae.
But now a new study published in the journal Science reveals that a different form of leprosy-causing bacteria — called Mycobacterium lepromatosis — was already circulating in the Americas for at least one thousand years.
Leprosy was therefore already affecting American indigenous peoples well before European colonization.
For years, it was believed Mycobacterium leprae bacteria were the only cause of leprosy. That changed with the discovery of a new leprosy-causing Mycobacterium in 2008. Image: public domain
Mycobacterium lepromatosis in America
The study authors analyzed more than 800 samples taken from ancient remains in Canada and Argentina.
The genomes of the bacteria taken from the samples were reconstructed, analyzed, and dated.
Comparisons between the samples showed the bacterial genomes were of distinctive branches of the lepromatosis species at each end of the continent.
However, they remained genetically similar. This suggested that the bacteria species had spread rapidly across the Americas, probably covering the landmass in just a few hundred years.
Leprosy is caused by two bacteria species, not one.
Leprosy is an ancient disease
Leprosy has been infecting humans for thousands of years. Skeletal records from 2,000BCE have been found in India with traces of the disease caused by Mycobacterium leprae.
These are matched by textual records of leprosy cases in ancient literature from Indian, Chinese and African civilizations, as well as stories in the Abrahamic religions.
Often, these ancient descriptions associated the affliction with stigmas of immorality or ritual uncleanliness.
But in 1874 the Norwegian doctor Gerhard Armauer Hansen discovered that leprosy was caused by the microscopic organism Mycobacterium leprae.
In 2008, doctors in Mexico found another leprosy-causing bacteria species — Mycobacterium lepromatosis — in a leprosy patient.
Before this, it was believed leprae was the only pathogen capable of causing the disease. Now both forms of the bacteria are known to cause it.
Leprosy has been stigmatized around the world for thousands of years, but with quick medical treatment, its dangerous symptoms can be reduced Image: Nyein Chan Naing/dpa/picture alliance
Europeans spread diseases, leprosy too
Nicolas Rascovan, head of the Microbial Paleogenomics Unit at the Pasteur Institut in France led the investigation. He and his colleagues estimate lepromatosis and leprae diverged from a common ancestor about one million years ago.
"The diversification happened probably independent of humans," Rascovan told DW.
The arrival of the first European fleets to the Americas in 1492 marked the introduction of new diseases to the Americas. Leprosy — in the form of the leprae bacterium — was among them.
Archaeological evidence has shown leprae migrated with human groups out of Africa and into Asia and Europe around 40,000 years ago.
Its introduction to the Americas along with other diseases by Europeans devastated indigenous communities and intensified the impact of pathogens that were already circulating before colonization.
The discovery of lepromatosis' longer history on the continent further highlights the diversity of pathogens and their complex relationship with humans throughout history, said Rascovan.
"Europeans had a very important impact by bringing this new species [leprae] that was absent in America," he said.
Indonesian leprosy survivors stepping over social stigmas
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
Leprosy track and trace
Rascovan hopes the presence of lepromatosis in the archeological record will improve understanding of pre-colonial disease, especially in the absence of written records.
In addition, the study helps understand modern cases of leprosy, especially how it could make the jump from animals like squirrels to humans.
"Our work is giving the kick start to really start analyzing, monitoring and understanding the diversity of natural reservoirs [disease carriers],' said Rascovan.
He said monitoring the disease and preventing spillovers from animals to humans should be a priority.
The disease is still prevalent today — 200,000 cases are reported each year globally. Brazil, India and Indonesia still report more than 10,000 new cases annually, according to WHO data.
The disease presents as multiple numbing skin lesions. If left untreated, the disease can result in nerve damage, muscle weakness, paralysis and blindness. Today, leprosy can be treated with antibiotics, but ancient sufferers weren't so fortunate.
Edited by: Fred Schwaller
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Int'l Business Times
a day ago
- Int'l Business Times
The Risks of Foreign Investment in U.S. Life Sciences Companies — Why Founders Should Take Heed
In recent years, Chinese investment in U.S. and global biotech and medtech has increased significantly. These partnerships can serve as strategic footholds, raising complex questions around security, sovereignty, and long-term strategy. Consider Grand Pharmaceutical Group, also known as Yuanda Pharmaceutical and Grand Pharma, which jointly acquired Australian firm Sirtex Medical, forged a nuclear medicine collaboration with Sirtex Medical U.S., and took an 87.5% stake in BlackSwan Vascular, a U.S.-based developer of vascular embolization technologies. On the surface, Grand Pharma looks like a modern success story. Hu Kaijun, a Chinese billionaire, holds a majority stake in Grand Pharma, positioning him as a key figure in the company's global expansion in the life sciences sector. Under his leadership, Grand Pharma has diversified its portfolio through strategic acquisitions and collaborations, enhancing its presence in the international market. But for U.S. life sciences stakeholders, don't be misled: Grand Pharma's rise isn't just a story of business savvy—it's a case study in how state-backed capital can reshape a company. And for founders, it's a reminder that funding sources can carry strategic baggage. Grand Pharma's aggressive expansion may reflect a broader trend of Chinese firms investing in advanced markets to access Western R&D and expand China's presence more deeply in the future of global biomedical innovation—a trend that raises serious concerns for U.S. interests. From State-Owned Roots to Global Reach Through strategic investments and collaborations, Kaijun and Grand Pharma continue to expand their footprint, resulting in the transfer of cutting-edge medical technologies from European and U.S. startups to China. Behind Grand Pharma's rapid rise lies a more complex history—one that raises questions about influence, oversight, and strategic intent. Before Grand Pharma was a global healthcare investor, it was a modest state-owned enterprise (SOE) in China under the purview of the Poverty Alleviation Office. Its mission: deliver pharmaceutical products as a public good, not a profit engine. But in the late 1990s and early 2000s, that began to change. A 2013 investigation by China Finance (CNFINA) suggested that Kaijun played a significant role in transforming the SOE into China Grand Enterprises through a series of complex transactions that have raised questions about corporate governance and asset valuation. One notable transaction highlighted in the CNFINA report involves Yanhuang Real Estate, a private firm not previously affiliated with the company. The firm purchased 50% of China Grand Enterprises from two state-owned shareholders for 50 million yuan. This transaction was justified using China Grand's initial registered capital of 100 million yuan. However, estimates based on the net assets held by China Grand at the time suggested that those shares were worth at least 145 million yuan, indicating a potential undervaluation of approximately 95 million yuan. The CNFINA report details that two additional state-owned entities transferred their 50% stake to four private investment firms, including Beijing Taihua Yongchang Investment and Beijing Dongfang Weichuang, for similarly underpriced amounts based on outdated registered capital. CNFINA's analysis estimated the value of these two transfers combined to have resulted in a total undervaluation of over 218 million yuan. This suspicious restructuring is significant because it offers a window into how power and capital were initially consolidated, and under what terms. Transactions that undervalue assets and move them out of public hands raise fundamental concerns about transparency, governance, and intent. When such origins lead to foreign acquisitions in sensitive sectors like biotechnology, it becomes even more important to scrutinize the business culture and strategic motivations behind the capital. In short, where the wealth comes from and how it was made offer important clues into how business leaders operate their companies. The Fine Print of Chinese Capital For U.S. life sciences startups, the lesson is clear: capital isn't neutral. The wrong investor can bring not just regulatory headaches but long-term strategic consequences. A growing list of cases tells a cautionary tale. Sirtex Medical When Grand Pharma and CDH Investments outbid Varian by a reported 20% to acquire Sirtex Medical, observers raised questions about the surprisingly high acquisition price. Through its subsidiary Chengdu Shetai, Grand Pharma has since leveraged Sirtex's platform to accelerate its development of nuclear medicine therapies. In cases of majority foreign ownership, especially by companies with potential state affiliations, it invites questions about data governance, manufacturing control, and regulatory visibility. More Lessons from BGI, WuXi, and Others Grand Pharma isn't the only example. Chinese biotech giants like BGI Group and WuXi AppTec have drawn attention in recent years over concerns related to data use, military ties, and participation in U.S. research networks. These cases underscore a growing sensitivity: capital flows from companies with strategic state interests may pose challenges in sensitive sectors like life sciences. A recent TechTimes article breaks down the core risks facing U.S. life sciences companies in the face of growing Chinese investment, from academic partnerships enabling access to sensitive research to financial ties that quietly shift control, and nefarious enterprises evading regulatory scrutiny. The piece argues that while the proposed BIOSECURE Act legislation is a step in the right direction, it lacks the enforcement teeth needed to truly safeguard American innovation in the life sciences sector. Ultimately, U.S. biotech and medtech startups must take proactive responsibility for who they partner with because policy alone won't protect what's not carefully guarded from the start. A Critical Reminder for Founders and CEOs: Capital Comes with Consequences U.S. life sciences startups face an increasingly complex landscape. Fast, global capital may seem like an obvious win, but it can introduce long-term complications. These include heightened regulatory oversight, potential deal restrictions, and reputational considerations. As geopolitical tensions evolve, particularly between the U.S. and China, biotech and medtech are emerging as points of scrutiny. In an interview on Chinese firms facing U.S. Commerce Department action related to AI, Gordon Chang, a senior fellow at the Gatestone Institute and a specialist on U.S.-China relations, stated, "all Chinese companies are a threat." While his comment was made in the context of national security and advanced technologies, it reflects a broader concern among some policymakers and analysts: that Chinese firms, regardless of sector, may operate with implicit state alignment, especially when national strategic interests are involved. For biotech and medtech companies, choosing the right partner now depends as much on who they are as what they offer. For the foreseeable future, U.S. startups should approach foreign investment, especially from state-influenced entities, with caution and care. This isn't just about one company or one country. It's about building resilient innovation ecosystems that can withstand geopolitical shifts while preserving trust, competitiveness, and scientific integrity.
DW
3 days ago
- DW
Health risks of synthetic drug use in Europe still unknown – DW – 06/05/2025
An EU drug report shows synthetic substances are on an upward trend. Drugs like cathinones are now made in Europe to keep up with demand. The health risks are largely unknown. What you need to know: Synthetic stimulants like cathinones continue to rise in Europe Researchers lack knowledge about the long-term health risks of synthetic drug use Cocaine remains Europe's illicit drug of choice, and it's moving from big cities to small towns Fentanyl and nitazene use are increasing, driven by a ban on opium poppy cultivation in Afghanistan The European Union Drugs Agency (EUDA) monitored 1,000 new psychoactive substances at the end of 2024 and found that local drug users were increasingly consuming new forms of synthetic drugs. This has been the dominant trend in Europe over the past 5-10 years. But what is new is that increasing amounts of these synthetic drugs are now being produced in Europe — previously, they were largely trafficked from India, China or the Middle East. "This is a result of the demand for taking synthetic [drugs]," said Andrew Cunningham, head of policy, crime and markets at the EUDA in Lisbon, Portugal. Cocaine, however, is still Europe's most popular illicit stimulant drug. Imported from Latin American countries like Ecuador and Colombia, about 4.6 million Europeans used cocaine in 2024. The report also shows more Europeans are taking multiple drugs at the same time. As in previous years, so-called polysubstance use is the leading cause of drug deaths in Europe. The findings were published in the European Drug Report 2025 , June 5. Why is synthetic drug use a problem? Synthetic drug use is a major public health concern. Many synthetic substances have very high potency, and because they are relatively new and ever-evolving, scientists have not been able to track the long-term effects. The report shows that Europeans are increasingly using cathinones, either in combination with, or instead of, amphetamines and MDMA. Cathinones, such as 3-MMC (mephedrone), are synthetic stimulants, which have "gained recreational popularity over the past 20 years in Europe," said Jan Ramaekers, a psychopharmacologist at Maastricht University in the Netherlands. Ramaekers said the long-term health effects of cathinones were not well known. Researchers needed to better understand consumption patterns among users: What is a "normal" dose? How does it range? What is lethal? "We need controlled studies with 3-MMC in these 'normal' dose ranges that focus on health risks, but also on potential health benefits," said Ramaekers. Most cathinones were imported from India and China, primarily through the Netherlands. But production has steadily moved to Central Asia and Europe, "influenced by the Ukraine war," said Cunningham. Legal highs: Addictive and dangerous To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Cocaine spreading from cities to smaller towns A significant amount of global cocaine product ends up in Europe. For the seventh year in a row, record quantities of cocaine were seized by EU countries, amounting to 419 tons in 2023, up from 323 tons in 2022. "It's a very significant amount considering global cocaine production is estimated at 2,600 tons per year," he said. But it's not just cocaine: Wastewater analysis in 128 European cities found overall increases in cocaine, but also MDMA and amphetamine use in 2024. The analysis suggests that urban patterns of drug use in big cities may be spreading to smaller towns. Cunningham, whose team tracks the effects of geopolitical situations on Europe's drug market, said most of Europe's cocaine (70%) comes from Colombia. "Global [cocaine] production is up every year since 2016 after the Colombian government made a [peace] deal with FARC," he said. FARC, also known as the Revolutionary Armed Forces of Colombia, were a Marxist militant group, suspected of involvement in illicit drug trade. Large seizures in Europe's ports show drug traffickers continue to smuggle the drug in from the sea. In 2024, Spain reported its largest ever seizure of cocaine (13 tons), concealed in bananas originating in Ecuador. How Europe became addicted to cocaine To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Deadly synthetic opioids on the rise The EUDA report estimates there were 7,500 drug-induced deaths in Europe in 2023, the majority of which were due to opioid drugs. Fake medicines containing synthetic opiates called nitazenes increased in at least 12 European countries in 2024. Some nitazene compounds are even stronger than fentanyl, which itself is 50 times stronger than heroin and has an extremely high risk of overdose. Synthetic opioids have been a major issue in the US for years, but the report shows they are a growing problem on the European drug market, too. "We fear an increase in synthetic opioids, such as fentanyl and nitazenes, on the illegal drug market, particularly as a result of the ban on opium poppy cultivation in Afghanistan," said Daniel Deimel, an addiction expert at Nuremberg Technical University, Germany. Fentanyl, America's silent killer To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video In recent months, there has been an increase in overdose clusters in Europe, which, Deimel said, may be a result of people mixing synthetic opioids with heroin. "Tests in drug consumption rooms in Germany have shown evidence of fentanyl or nitazene in heroin. If these substances become more common, the number of overdoses and fatal overdoses is likely to increase," said Deimel. Drug seizures in Europe have found nitazenes in fake prescription drugs, mimicking oxycodone or benzodiazepines bought on the illegal drug market. These fake pills have much higher potency and carry a significant risk of drug poisoning and overdose, especially as people do not know the drugs they are taking contain nitazenes. The EUDA report shows authorities seized 10 kilograms of nitazenes powder in 2023 — potentially sufficient to make millions of pills containing enough nitazenes to cause an overdose. Many experts are calling for more drug checking services to detect which substances are circulating on the drug scene. This allows public warnings to be issued when dangerous compounds are found in substances. Edited by: Zulfikar Abbany Source: The EU Drug Report 2025, EUDA, June 5 2025
DW
4 days ago
- DW
Secret leprosy infected the Americas before European arrival – DW – 06/04/2025
European colonizers were thought to have brought leprosy to the Americas, but a new study reveals it existed there for thousands of years and spread by a recently discovered bacteria species. What to know: Leprosy is one of the oldest human diseases and originated in Eurasia or Africa. A new study has found a different species of leprosy-causing bacteria existed in the Americas before European settlement. Scientists once believed Europeans brought leprosy to the American continents via infection from the bacterial species Mycobacterium leprae. But now a new study published in the journal Science reveals that a different form of leprosy-causing bacteria — called Mycobacterium lepromatosis — was already circulating in the Americas for at least one thousand years. Leprosy was therefore already affecting American indigenous peoples well before European colonization. For years, it was believed Mycobacterium leprae bacteria were the only cause of leprosy. That changed with the discovery of a new leprosy-causing Mycobacterium in 2008. Image: public domain Mycobacterium lepromatosis in America The study authors analyzed more than 800 samples taken from ancient remains in Canada and Argentina. The genomes of the bacteria taken from the samples were reconstructed, analyzed, and dated. Comparisons between the samples showed the bacterial genomes were of distinctive branches of the lepromatosis species at each end of the continent. However, they remained genetically similar. This suggested that the bacteria species had spread rapidly across the Americas, probably covering the landmass in just a few hundred years. Leprosy is caused by two bacteria species, not one. Leprosy is an ancient disease Leprosy has been infecting humans for thousands of years. Skeletal records from 2,000BCE have been found in India with traces of the disease caused by Mycobacterium leprae. These are matched by textual records of leprosy cases in ancient literature from Indian, Chinese and African civilizations, as well as stories in the Abrahamic religions. Often, these ancient descriptions associated the affliction with stigmas of immorality or ritual uncleanliness. But in 1874 the Norwegian doctor Gerhard Armauer Hansen discovered that leprosy was caused by the microscopic organism Mycobacterium leprae. In 2008, doctors in Mexico found another leprosy-causing bacteria species — Mycobacterium lepromatosis — in a leprosy patient. Before this, it was believed leprae was the only pathogen capable of causing the disease. Now both forms of the bacteria are known to cause it. Leprosy has been stigmatized around the world for thousands of years, but with quick medical treatment, its dangerous symptoms can be reduced Image: Nyein Chan Naing/dpa/picture alliance Europeans spread diseases, leprosy too Nicolas Rascovan, head of the Microbial Paleogenomics Unit at the Pasteur Institut in France led the investigation. He and his colleagues estimate lepromatosis and leprae diverged from a common ancestor about one million years ago. "The diversification happened probably independent of humans," Rascovan told DW. The arrival of the first European fleets to the Americas in 1492 marked the introduction of new diseases to the Americas. Leprosy — in the form of the leprae bacterium — was among them. Archaeological evidence has shown leprae migrated with human groups out of Africa and into Asia and Europe around 40,000 years ago. Its introduction to the Americas along with other diseases by Europeans devastated indigenous communities and intensified the impact of pathogens that were already circulating before colonization. The discovery of lepromatosis' longer history on the continent further highlights the diversity of pathogens and their complex relationship with humans throughout history, said Rascovan. "Europeans had a very important impact by bringing this new species [leprae] that was absent in America," he said. Indonesian leprosy survivors stepping over social stigmas To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video Leprosy track and trace Rascovan hopes the presence of lepromatosis in the archeological record will improve understanding of pre-colonial disease, especially in the absence of written records. In addition, the study helps understand modern cases of leprosy, especially how it could make the jump from animals like squirrels to humans. "Our work is giving the kick start to really start analyzing, monitoring and understanding the diversity of natural reservoirs [disease carriers],' said Rascovan. He said monitoring the disease and preventing spillovers from animals to humans should be a priority. The disease is still prevalent today — 200,000 cases are reported each year globally. Brazil, India and Indonesia still report more than 10,000 new cases annually, according to WHO data. The disease presents as multiple numbing skin lesions. If left untreated, the disease can result in nerve damage, muscle weakness, paralysis and blindness. Today, leprosy can be treated with antibiotics, but ancient sufferers weren't so fortunate. Edited by: Fred Schwaller
